| 中國醫藥大學 |
2003-08 |
Neoadjuvant Androgen Deprivation and Definitive Radiotherapy in Localized and Locally Advanced Prostate Cancer
|
吳錫金(Hsi-chin Wu); 謝登富(Deng-fu Hsieh); 張兆祥(Chao-hsian Chang); 陳汶吉(Wen-chi Chen); 陳昶仲(Chang-chung Chen); 梁基安(Ji-an Liang); 林芳仁(Fang-jen Lin) |
| 國立臺灣大學 |
2014 |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
|
Wang, Chia-Chun; Liang, Jin-Tung; Tsai, Chiao-Ling; Chen, Yu-Hsuan; Lin, Yu-Lin; Shun, Chia-Tung; Cheng, Jason Chia-Hsien; 林育麟; 成佳憲; 王嘉檇; 陳育瑄; 蔡巧琳; 孫家棟; 梁金銅 |
| 臺大學術典藏 |
2021-03-18T02:02:45Z |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: Early outcome and technical impact on toxicity
|
Wang C.-C.;Liang J.-T.;Tsai C.-L.;Chen Y.-H.;Lin Y.-L.;Chia-Tung Shun;Cheng J.C.-H.; Wang C.-C.; Liang J.-T.; Tsai C.-L.; Chen Y.-H.; Lin Y.-L.; CHIA-TUNG SHUN; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-05-03T02:20:58Z |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: Early outcome and technical impact on toxicity
|
Wang C.-C.; JIN-TUNG LIANG; Tsai C.-L.; Chen Y.-H.; Lin Y.-L.; Shun C.-T.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-05-21T07:17:47Z |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: Early outcome and technical impact on toxicity
|
Wang C.-C.; Liang J.-T.; CHIAO-LING TSAI; Chen Y.-H.; Lin Y.-L.; Shun C.-T.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-06-29T03:58:36Z |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: Early outcome and technical impact on toxicity
|
Chia-Chun Wang; Liang J.-T.; Tsai C.-L.; Chen Y.-H.; Lin Y.-L.; Shun C.-T.; Cheng J.C.-H. |
| 臺大學術典藏 |
2022-05-05T08:48:56Z |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: Early outcome and technical impact on toxicity
|
CHIA-CHUN WANG; Liang J.-T.; Tsai C.-L.; Chen Y.-H.; Lin Y.-L.; Shun C.-T.; Cheng J.C.-H. |
| 國立臺灣大學 |
2013 |
Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer
|
Liao, Wei-Yu; Chen, Jin-Hsin; Wu, Muzo; Shih, Jin-Yuan; Chen, Kuan-Yuh; Ho, Chao-Chi; Yang, James Chih-Hsin; Yu, Chong-Jen; 廖唯昱; 陳冠宇; 余忠仁; 何肇基; 施金元 |
| 臺大學術典藏 |
2020-05-26T09:27:02Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y;Chen J.-H;Wu M;Shih J.-Y;Chen K.-Y;Ho C.-C;Chih-Hsin Yang;Yu C.-J.; Liao W.-Y; Chen J.-H; Wu M; Shih J.-Y; Chen K.-Y; Ho C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:46:29Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Chen K.-Y.; Wu M.; Shih J.-Y.; Chen J.-H.; Liao W.-Y.; CHAO-CHI HO; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:47Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Yang J.C.-H.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Wu M.; Chen J.-H.; Liao W.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:14Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Wei-Yu Liao;Chen J.-H.;Wu M.;Shih J.-Y.;Chen K.-Y.;Ho C.-C.;Yang J.C.-H.;Yu C.-J.; WEI-YU LIAO; Chen J.-H.; Wu M.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-04-29T02:38:38Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Anonymous |
| 臺大學術典藏 |
2021-04-29T05:09:07Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y.; Chen J.-H.; Wu M.; Shih J.-Y.; KUAN-YU CHEN; Ho C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:01:58Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y.; Chen J.-H.; Wu M.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; Yang J.C.-H.; CHONG-JEN YU |
| 國家衛生研究院 |
2025-07 |
Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L;D'Alessio, A;Fulgenzi, CAM;Yarchoan, M;Marron, T;Blanter, J;Torkpour, A;Lombardi, P;Baretti, M;Crowley, F;Hsu, C;Cortellini, A;Su, YY;Lee, PC;Eid, JR;Kaseb, A;Pinato, DJ |
| 臺北醫學大學 |
2006 |
Neoadjuvant Leuplin treatment reduces the operation time and blood loss and pelvic adhesion of laparoscopic enucleation of endometriomas
|
曾啟瑞; Chen PH; Chuang CC; Chen D; Hsu HC; Tzeng CR; |
| 國立成功大學 |
2023 |
Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case–control study
|
Tsai, J.-H.;Li, C.-L.;Yeh, D.-C.;Hung, C.-S.;Hung, C.-C.;Lin, C.-Y.;Kuo, Y.-L. |
| 臺大學術典藏 |
2022-09-21T01:28:22Z |
Neoadjuvant Stereotactic Body Radiation Therapy for Spine Metastases
|
Chun Lin, Pao; Ming Hsu, Feng; Chen, Yi Hsing; FU-REN XIAO |
| 臺大學術典藏 |
2019 |
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study
|
Slamon D.; Thompson A.M.; Fraser Symmans W.; Hurvitz S.A.;Martin M.;Jung K.H.;Chiun-Sheng Huang;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Fasching P.A.;Afenjar K.;Spera G.;Lopez-Valverde V.;Song C.;Trask P.;Boulet T.;Sparano J.A.;Fraser Symmans W.;Thompson A.M.;Slamon D.; Hurvitz S.A.; Martin M.; Jung K.H.; CHIUN-SHENG HUANG; Harbeck N.; Valero V.; Stroyakovskiy D.; Wildiers H.; Campone M.; Boileau J.-F.; Fasching P.A.; Afenjar K.; Spera G.; Lopez-Valverde V.; Sparano J.A.; Boulet T.; Trask P.; Song C. |
| 臺大學術典藏 |
2018-09-10T18:05:39Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.-S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.-F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.-J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D.; Hurvitz, S.A.; CHIUN-SHENG HUANGet al. |
| 臺大學術典藏 |
2020-03-23T07:18:55Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Fresco R.; Helms H.-J.; Xu J.; Lin Y.G.; Sparano J.; Slamon D.; Beckmann M.W.; Afenjar K.; Campone M.; Boileau J.-F.; Wildiers H.; Stroyakovskiy D.; Harbeck N.; Valero V.; Thompson A.M.; CHIUN-SHENG HUANG; Jung K.H.; Symmans W.F.; Martin M.; Hurvitz S.A.; Hurvitz S.A.;Martin M.;Symmans W.F.;Jung K.H.;Chiun-Sheng Huang;Thompson A.M.;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Beckmann M.W.;Afenjar K.;Fresco R.;Helms H.-J.;Xu J.;Lin Y.G.;Sparano J.;Slamon D. |
| 中山醫學大學 |
2020 |
Neoadjuvant Versus Definitive Concurrent Chemoradiotherapy In Stage III Esophageal Cancer Patients
|
Chen, HL; Chou, YH; Lee, Y; Tseng, HC |
| 國立成功大學 |
2024-06-1 |
Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
|
Shitara;Kohei;Bang;Yung-Jue;Wyrwicz;Lucjan, S.;Rha;Young, Sun;Oshima;Takashi;Bartolomeo, Di;Maria;Park;Young-Kyu;Lonardi;Sara;Weber;Yanez, Patricio Eduardo;Yen;Chia-Jui;Metges;Jean-Philippe;Garrido;Marcelo;Moehler;Markus, H.;Pelles-Avraham;Sharon;Yong;Wei-Peng;Spallanzani;Andrea;Jensen;Erin;Krishnan;Radha;Shih;Chie-Schin;Al-Batran;Salah-Eddin |
| 中國醫藥大學 |
2001-04 |
Neoadjuvent chemotherapy and breast conserving surgery
|
張嘉麟 |
